The past week has seen the resolution of 2 high-profile biosimilar patent infringement cases. In the first, a district court’s ruling was upheld, and in the second, a reference drug sponsor agreed to drop its infringement claims—with prejudice—against a biosimilar developer.
The past week has seen the resolution of 2 high-profile biosimilar patent infringement cases. In the first, a district court’s ruling was upheld, and in the second, a reference drug sponsor agreed to drop its infringement claims—with prejudice—against a biosimilar developer.
Amgen v Apotex
On Monday, the US Court of Appeals for the federal circuit upheld a district court verdict in Amgen v Apotex, in which the court ruled that Apotex did not infringe on Amgen’s patent 8,952,138 (the ‘138 patent), which covers a method of refolding proteins expressed in non-mammalian cells, when it developed its proposed filgrastim and pegfilgrastim biosimilars.
Big Molecule Watch reported that, in Amgen’s October appeal before 3 judges, most of the panel’s questions centered on whether patent infringement in Biologics Price Competition and Innovation Act (BPCIA) litigation can be demonstrated by relying on information in an abbreviated Biologics License Application (aBLA), as Amgen had argued, and whether Apotex should have been allowed to rely in court on arguments that the biosimilar developer had not raised in a timely fashion.
In the November ruling, the appellate court affirmed the court’s ruling that Amgen failed to prove direct infringement on its patents by Apotex. The court’s opinion stated that “…it was not Apotex’s burden to prove non-infringement…It was Amgen’s burden to prove that Apotex’s processes would infringe the ‘138 patent.”
Janssen v Samsung Bioepis
Johnson & Johnson division Janssen has voluntarily dropped its patent suit against biosimilar developer Samsung Bioepis in a lawsuit regarding its infliximab biosimilar, Renflexis. Janssen had filed the suit in May, claiming that Samsung Bioepis had both violated the BPCIA and infringed on 3 patents.
After the Supreme Court’s decision in Amgen v Sandoz, the district court dismissed the claims concerning the BPCIA as moot. Janssen and Samsung Bioepis continued to litigate US patents 7,598,083 and 6,900,056 (both of which cover chemically defined media) and 6,773,600 (which covers the use of a clathrate modifier to promote passage of proteins during nanofiltration).
However, on November 10, the parties filed documents to dismiss the remaining claims of patent infringement. The dismissal was filed with prejudice with respect to claims and defenses related to cell culture and downstream purification processes; thus, Janssen cannot file a future suit against Samsung Bioepis over these particular claims.
“Janssen’s withdrawal of the lawsuit marks a positive step towards improving patient access to biosimilars in the United States,” Mingi Hyun, a Samsung Bioepis spokesperson, told Reuters.
Samsung Bioepis launched Renflexis, the second FDA approved infliximab biosimilar, in the United States in July 2017.
HHS Praises Biosimilars Savings but Opportunities to Reduce Part B Spending Remain
November 28th 2023Although biosimilars have already generated savings for Medicare Part B programs and beneficiaries, opportunities for substantial reductions in spending remain, according to a report from the HHS.
Biosimilar Business Roundup for October 2023—Podcast Edition
November 5th 2023On this episode, we discuss the biggest news to come out of October 2023, including 3 regulatory approvals, 2 complete response letters, and new data and industry insights that have the potential to impact the entire US biosimilar industry.
Eye on Pharma: Adalimumab Updates; New Eylea Biosimilar Lawsuit; Canada Gains Stelara Biosimilar
November 22nd 2023Several companies make moves to further their adalimumab biosimilars, Regeneron sues Celltrion over biosimilar for Eylea (aflibercept), and Health Canada grants marketing authorization for biosimilar referencing Stelara (ustekinumab).
Biosimilars Business Roundup For August 2023—Podcast Edition
September 5th 2023On this episode, we’re giving an overview of some of the biggest stories in the business space regarding biosimilars, like the approval of the first neurology biosimilar, growth projections from company quarterly expense reports, and some analyses about the health of the market.
AMCP Nexus: Panelists Share Current Scope of Biosimilar Industry
October 26th 2023Panelists at the Academy of Managed Care Pharmacy (AMCP) Nexus meeting chronicled the current state of the US biosimilar market, including current policies impacting the market, recent regulatory decisions, and the developing arguments around requirements for clinical efficacy studies.
Report: Conflicting Guidelines, Rebate Walls Are Major Factors Determining Biosimilar Uptake
October 24th 2023Samsung Bioepis’ most recent biosimilar market report identified inconsistent medical guidelines, challenges with access and rebates, and acute vs chronic treatment duration as major factors influencing biosimilar uptake in the United States.